Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Remain Fit and Sound with These Exercise Fundamentals - 2Bayer reports positive results for blood thinner after 2023 setback
- 3Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- 4Vote In favor of Your Number one Cell phones
- 5How to see the Ursids, the final meteor shower of 2025
- Pick Your Favored kind of books
- Find the Standards of Powerful Cooperation: Accomplishing Cooperative energy and Coordinated effort
- Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- Unwind: Four Extraordinary Spa Resorts On the planet
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- Horses really can smell our fear, new study finds
- Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- A definitive Manual for the 5 Off-road Bicycles Available
